1 | paladin labs inc announces | | | | | | | 4 | 0.97% |
2 | labs inc to commercialize | | | | | | | 3 | 0.73% |
3 | paladin labs inc to | | | | | | | 3 | 0.73% |
4 | contact customer service medical | | | | | | | 2 | 0.49% |
5 | investigator initiated research grants | | | | | | | 2 | 0.49% |
6 | grants program investigator initiated | | | | | | | 2 | 0.49% |
7 | fellowship grants program investigator | | | | | | | 2 | 0.49% |
8 | and fellowship grants program | | | | | | | 2 | 0.49% |
9 | grants community grants our | | | | | | 2 | 0.49% |
10 | community grants our products | | | | | | 2 | 0.49% |
11 | investors news and events | | | | | | | 2 | 0.49% |
12 | inc investors news and | | | | | | | 2 | 0.49% |
13 | endo inc investors news | | | | | | | 2 | 0.49% |
14 | team endo inc investors | | | | | | | 2 | 0.49% |
15 | management team endo inc | | | | | | | 2 | 0.49% |
16 | community contact customer service | | | | | | 2 | 0.49% |
17 | research grants community grants | | | | | | 2 | 0.49% |
18 | a highly focused generics | | | | | | | 2 | 0.49% |
19 | labs inc announces approval | | | | | | | 2 | 0.49% |
20 | inc announces the launch | | | | | | | 2 | 0.49% |
21 | for paladin labs inc | | | | | | | 2 | 0.49% |
22 | announces the launch of | | | | | | | 2 | 0.49% |
23 | highly focused generics and | | | | | | | 2 | 0.49% |
24 | inc announces approval of | | | | | | | 2 | 0.49% |
25 | with advanced parkinsons disease | | | | | | | 1 | 0.24% |
26 | transplant patients is now | | | | | | | 1 | 0.24% |
27 | patients is now reimbursed | | | | | | | 1 | 0.24% |
28 | is now reimbursed in | | | | | | | 1 | 0.24% |
29 | manitoba and saskatchewan 23oct2019 | | | | | | | 1 | 0.24% |
30 | patients with advanced parkinsons | | | | | | | 1 | 0.24% |
31 | for patients with advanced | | | | | | | 1 | 0.24% |
32 | now reimbursed in ontario | | | | | | | 1 | 0.24% |
33 | reimbursed in ontario quebec | | | | | | | 1 | 0.24% |
34 | 23oct2019 movapo® apomorphine hydrochloride | | | | | | | 1 | 0.24% |
35 | saskatchewan 23oct2019 movapo® apomorphine | | | | | | | 1 | 0.24% |
36 | and saskatchewan 23oct2019 movapo® | | | | | | | 1 | 0.24% |
37 | canadian provinces 31jul2019 helsinn | | | | | | | 1 | 0.24% |
38 | advanced parkinsons disease now | | | | | | | 1 | 0.24% |
39 | inc to commercialize pracinostat | | | | | | | 1 | 0.24% |
40 | tablets in canada 25jul2018 | | | | | | | 1 | 0.24% |